Zkusit zdarma
Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc.

ZNTL
Cena:
$ 4.06
-0.08 (-1.93%)
Valuace
70
Růst
30
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

17:39 21-05-2026

In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the comb...

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

17:39 21-05-2026

SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clini...

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

16:05 13-05-2026

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clin...

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

16:05 12-05-2026

400mg QD 5:2 selected as azenosertib monotherapy pivotal study dose based on favorable benefit-risk ...

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

8:00 05-05-2026

Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy ...

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

10:27 21-04-2026

Results from Part 1 of the Phase 1b MUIR trial to be presented at annual meeting in June Results fro...

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

15:15 17-04-2026

SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a cl...

What's Behind The Surge In Zentalis Stock?

What's Behind The Surge In Zentalis Stock?

12:44 10-04-2026

Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) shares are surging Friday after a Guggenheim analyst r...

Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

8:00 09-04-2026

Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg ...

Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates

Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates

16:05 26-03-2026

On track for DENALI Part 2a dose confirmation in 1H 2026 DENALI Part 2 trial topline readout expecte...

Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

16:30 17-03-2026

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a cl...

Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Almitas Capital LLC

Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Almitas Capital LLC

3:31 15-03-2026

Almitas Capital LLC trimmed its position in Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) by 71.4% d...

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

8:00 18-02-2026

SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clin...

Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon

Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon

5:02 17-02-2026

Zentalis Pharmaceuticals (NASDAQ: ZNTL) executives outlined a strategy centered on advancing its WEE...

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

16:05 03-02-2026

SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clin...

Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

8:00 06-01-2026

Completed enrollment in DENALI Part 2a; dose confirmation expected in 1H 2026 DENALI Part 2 trial to...

Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market

Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market

14:07 09-12-2025

Zentalis has taken a serious beating in 2025 to date, as the market continues to value their pipelin...

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

16:05 10-11-2025

DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on trac...

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

8:15 03-11-2025

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clin...

Zentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Zentalis Pharmaceuticals, Inc. (ZNTL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

12:27 09-09-2025

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL ) Morgan Stanley 23rd Annual Global Healthcare Conferenc...

close

ZENTALIS PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCE

03-02-2026
SAN DIEGO, FEB. 03, 2026 (GLOBE NEWSWIRE) -- ZENTALIS® PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLIN...
Více zde

ZENTALIS PHARMACEUTICALS PROVIDES CORPORATE UPDATE AND HIGHLIGHTS KEY MILESTONES AND EXPECTED MOMENTUM IN THE AZENOSERTIB DEVELOPMENT PROGRAM FOR 2026

06-01-2026
COMPLETED ENROLLMENT IN DENALI PART 2A; DOSE CONFIRMATION EXPECTED IN 1H 2026 DENALI PART 2 TRIAL TO...
Více zde

ZENTALIS PHARMACEUTICALS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL PROGRESS

10-11-2025
DENALI PHASE 2 TRIAL EVALUATING AZENOSERTIB IN PATIENTS WITH CYCLIN E1-POSITIVE PROC REMAINS ON TRAC...
Více zde

ZENTALIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

03-11-2025
SAN DIEGO, NOV. 03, 2025 (GLOBE NEWSWIRE) -- ZENTALIS® PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLIN...
Více zde

ZENTALIS PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

03-11-2025
SAN DIEGO, NOV. 03, 2025 (GLOBE NEWSWIRE) -- ZENTALIS® PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLIN...
Více zde

ZENTALIS PHARMACEUTICALS ANNOUNCES FOUR AZENOSERTIB POSTERS PRESENTATIONS AT AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS

13-10-2025
PRESENTATIONS FEATURE DATA FROM FIRST-IN-HUMAN PHASE 1 STUDY INCLUDING CYCLIN E1 BIOMARKER FINDINGS,...
Více zde

ZENTALIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

01-10-2025
SAN DIEGO, OCT. 01, 2025 (GLOBE NEWSWIRE) -- ZENTALIS® PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLIN...
Více zde

ZENTALIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

02-09-2025
SAN DIEGO, SEPT. 02, 2025 (GLOBE NEWSWIRE) -- ZENTALIS® PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLI...
Více zde

ZENTALIS PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

28-08-2025
SAN DIEGO, AUG. 28, 2025 (GLOBE NEWSWIRE) -- ZENTALIS® PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLIN...
Více zde

ZENTALIS PHARMACEUTICALS APPOINTS JAMES B. BUCHER, JD, AS CHIEF LEGAL OFFICER AND CORPORATE SECRETARY

26-08-2025
SEASONED LIFE SCIENCES LEGAL EXECUTIVE BRINGS EXTENSIVE PUBLIC COMPANY EXPERIENCE, INCLUDING BROAD S...
Více zde

ZENTALIS PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL PROGRESS

06-08-2025
DENALI PHASE 2 TRIAL EVALUATING AZENOSERTIB IN PATIENTS WITH CYCLIN E1-POSITIVE PROC REMAINS ON TRAC...
Více zde

ZENTALIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

01-07-2025
SAN DIEGO, JULY 01, 2025 (GLOBE NEWSWIRE) -- ZENTALIS® PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLIN...
Více zde

ZENTALIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

02-06-2025
SAN DIEGO, JUNE 02, 2025 (GLOBE NEWSWIRE) -- ZENTALIS® PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLIN...
Více zde

ZENTALIS PHARMACEUTICALS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND OPERATIONAL PROGRESS

14-05-2025
FIRST PATIENT DOSED IN DENALI PART 2A CLINICAL TRIAL OF AZENOSERTIB IN PATIENTS WITH CYCLIN E1+ PROC...
Více zde

ZENTALIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

01-05-2025
SAN DIEGO, MAY 01, 2025 (GLOBE NEWSWIRE) -- ZENTALIS® PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLINI...
Více zde

ZENTALIS PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN DENALI PART 2 CLINICAL TRIAL OF AZENOSERTIB IN PATIENTS WITH CYCLIN E1+ PROC

28-04-2025
PHASE 2 REGISTRATION-INTENT TRIAL ENROLLING PART 2A DOSE CONFIRMATION ARMS TOPLINE DATA FROM DENALI ...
Více zde

ZENTALIS PHARMACEUTICALS ANNOUNCES POSTER PRESENTATION AT 2025 ASCO ANNUAL MEETING

23-04-2025
SAN DIEGO, APRIL 23, 2025 (GLOBE NEWSWIRE) -- ZENTALIS® PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLI...
Více zde

ZENTALIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

01-04-2025
SAN DIEGO, APRIL 01, 2025 (GLOBE NEWSWIRE) -- ZENTALIS® PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLI...
Více zde

ZENTALIS PHARMACEUTICALS REPORTS FULL YEAR 2024 FINANCIAL RESULTS AND OPERATIONAL UPDATES

26-03-2025
POSITIVE AZENOSERTIB CLINICAL DATA DEMONSTRATED CLINICALLY MEANINGFUL RESULTS IN PATIENTS WITH CYCLI...
Více zde

ZENTALIS PHARMACEUTICALS TO PRESENT MULTIPLE POSTERS AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2025

25-03-2025
ONE POSTER DEMONSTRATING CELL-FREE DNA MOLECULAR RESPONSE AS A POTENTIAL SURROGATE ENDPOINT TO MEASU...
Více zde

ZENTALIS PHARMACEUTICALS PRESENTS UPDATED CLINICAL DATA AT THE SOCIETY OF GYNECOLOGIC ONCOLOGY 2025 ANNUAL MEETING ON WOMEN'S CANCER

15-03-2025
AZENOSERTIB MEDIAN DURATION OF RESPONSE (MDOR) UPDATED TO 6.3 MONTHS IN THE ONGOING DENALI PART 1B C...
Více zde

ZENTALIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

03-03-2025
SAN DIEGO, MARCH 03, 2025 (GLOBE NEWSWIRE) -- ZENTALIS® PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLI...
Více zde

ZENTALIS PHARMACEUTICALS ANNOUNCES MULTIPLE DATA PRESENTATIONS AT SOCIETY OF GYNECOLOGIC ONCOLOGY 2025 ANNUAL MEETING ON WOMEN'S CANCER

03-03-2025
UPDATED CLINICAL DATA FROM ONGOING DENALI CLINICAL TRIAL OF AZENOSERTIB IN PATIENTS WITH PROC PRECLI...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZENTALIS PHARMACEUTICALS, INC. - ZNTL

01-03-2025
NEW YORK CITY, NY / ACCESS NEWSWIRE / MARCH 1, 2025 / POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHAL...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZENTALIS PHARMACEUTICALS, INC. - ZNTL

27-02-2025
NEW YORK, NY / ACCESS NEWSWIRE / FEBRUARY 27, 2025 / NEW YORK, FEBRUARY 27, 2025 (ACCESSWIRE) POMERA...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZENTALIS PHARMACEUTICALS, INC. - ZNTL

25-02-2025
NEW YORK , FEB. 25, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTOR...
Více zde

ZENTALIS PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

24-02-2025
SAN DIEGO, FEB. 24, 2025 (GLOBE NEWSWIRE) -- ZENTALIS® PHARMACEUTICALS, INC. (NASDAQ: ZNTL), A CLIN...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZENTALIS PHARMACEUTICALS, INC. - ZNTL

23-02-2025
NEW YORK, NY / ACCESS NEWSWIRE / FEBRUARY 23, 2025 / POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZENTALIS PHARMACEUTICALS, INC. - ZNTL

21-02-2025
NEW YORK, NY / ACCESS NEWSWIRE / FEBRUARY 21, 2025 / POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF...
Více zde

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZENTALIS PHARMACEUTICALS, INC. - ZNTL

19-02-2025
NEW YORK, NY / ACCESS NEWSWIRE / FEBRUARY 19, 2025 / POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-01-09 00:00:008-KStáhnout
2025-12-15 00:00:008-KStáhnout
2025-11-10 00:00:008-KStáhnout
2025-11-10 00:00:0010-QStáhnout
2025-08-26 01:00:008-KStáhnout
2025-08-26 00:00:008-KStáhnout
2025-08-06 01:00:008-KStáhnout
2025-08-06 01:00:0010-QStáhnout
2025-08-06 00:00:008-KStáhnout
2025-08-06 00:00:0010-QStáhnout
2025-06-18 01:00:008-KStáhnout
2025-06-18 00:00:008-KStáhnout
2025-06-02 01:00:008-KStáhnout
2025-06-02 00:00:008-KStáhnout
2025-05-20 01:00:008-KStáhnout
2025-05-20 00:00:008-KStáhnout
2025-05-14 01:00:008-KStáhnout
2025-05-14 01:00:0010-QStáhnout
2025-05-14 00:00:008-KStáhnout
2025-05-14 00:00:0010-QStáhnout
2025-04-28 01:00:008-KStáhnout
2025-04-28 00:00:008-KStáhnout
2025-03-26 00:00:008-KStáhnout
2025-03-26 00:00:0010-KStáhnout
2025-03-25 23:00:008-KStáhnout
2025-03-25 23:00:0010-KStáhnout
2025-03-17 00:00:008-KStáhnout
2025-03-16 23:00:008-KStáhnout
2025-01-29 00:00:008-KStáhnout
2025-01-28 23:00:008-KStáhnout
2025-01-28 00:00:008-KStáhnout
2025-01-27 23:00:008-KStáhnout
2024-11-13 00:00:008-KStáhnout
2024-11-12 23:00:008-KStáhnout
2024-11-12 00:00:0010-QStáhnout
2024-11-11 23:00:0010-QStáhnout
2024-09-16 01:00:008-KStáhnout
2024-09-16 00:00:008-KStáhnout
2024-08-09 01:00:008-KStáhnout
2024-08-09 01:00:0010-QStáhnout
2024-08-09 00:00:008-KStáhnout
2024-08-09 00:00:0010-QStáhnout
2024-06-21 01:00:008-KStáhnout
2024-06-21 00:00:008-KStáhnout
2024-06-03 01:00:008-KStáhnout
2024-06-03 00:00:008-KStáhnout
2024-05-29 01:00:008-KStáhnout
2024-05-29 00:00:008-KStáhnout
2024-05-07 01:00:008-KStáhnout
2024-05-07 01:00:0010-QStáhnout
2024-05-07 00:00:008-KStáhnout
2024-05-07 00:00:0010-QStáhnout
2024-04-11 01:00:008-KStáhnout
2024-04-11 00:00:008-KStáhnout
2024-04-09 01:00:008-KStáhnout
2024-04-09 00:00:008-KStáhnout
2024-02-27 00:00:008-KStáhnout
2024-02-27 00:00:0010-KStáhnout
2024-02-26 23:00:008-KStáhnout
2024-02-26 23:00:0010-KStáhnout
2024-02-15 00:00:008-KStáhnout
2024-02-14 23:00:008-KStáhnout
2024-01-25 00:00:008-KStáhnout
2024-01-24 23:00:008-KStáhnout
2024-01-08 00:00:008-KStáhnout
2024-01-07 23:00:008-KStáhnout
2023-11-06 00:00:008-KStáhnout
2023-11-06 00:00:0010-QStáhnout
2023-11-05 23:00:008-KStáhnout
2023-11-05 23:00:0010-QStáhnout
2023-10-06 01:00:008-KStáhnout
2023-10-06 00:00:008-KStáhnout
2023-09-13 01:00:008-KStáhnout
2023-09-13 00:00:008-KStáhnout
2023-08-09 01:00:008-KStáhnout
2023-08-09 01:00:0010-QStáhnout
2023-08-09 00:00:008-KStáhnout
2023-08-09 00:00:0010-QStáhnout
2023-06-16 01:00:008-KStáhnout
2023-06-16 00:00:008-KStáhnout
2023-06-15 01:00:008-KStáhnout
2023-06-15 00:00:008-KStáhnout
2023-06-06 01:00:008-KStáhnout
2023-06-06 00:00:008-KStáhnout
2023-06-05 01:00:008-KStáhnout
2023-06-05 00:00:008-KStáhnout
2023-05-26 01:00:008-KStáhnout
2023-05-26 00:00:008-KStáhnout
2023-05-10 01:00:008-KStáhnout
2023-05-10 01:00:0010-QStáhnout
2023-05-10 00:00:008-KStáhnout
2023-05-10 00:00:0010-QStáhnout
2023-04-26 01:00:008-KStáhnout
2023-04-26 00:00:008-KStáhnout
2023-04-17 01:00:008-KStáhnout
2023-04-17 00:00:008-KStáhnout
2023-03-10 00:00:008-KStáhnout
2023-03-09 23:00:008-KStáhnout
2023-03-09 00:00:008-KStáhnout
2023-03-08 23:00:008-KStáhnout
2023-03-01 00:00:008-KStáhnout
2023-03-01 00:00:0010-KStáhnout
2023-02-28 23:00:008-KStáhnout
2023-02-28 23:00:0010-KStáhnout
2023-02-13 00:00:008-KStáhnout
2023-02-12 23:00:008-KStáhnout
2023-01-09 00:00:008-KStáhnout
2023-01-08 23:00:008-KStáhnout
2022-11-09 00:00:008-KStáhnout
2022-11-09 00:00:0010-QStáhnout
2022-11-08 23:00:008-KStáhnout
2022-11-08 23:00:0010-QStáhnout
2022-09-27 01:00:008-KStáhnout
2022-09-27 00:00:008-KStáhnout
2022-09-12 01:00:008-KStáhnout
2022-09-12 00:00:008-KStáhnout
2022-08-09 01:00:008-KStáhnout
2022-08-09 01:00:0010-QStáhnout
2022-08-09 00:00:008-KStáhnout
2022-08-09 00:00:0010-QStáhnout
2022-07-22 01:00:008-KStáhnout
2022-07-22 00:00:008-KStáhnout
2022-06-27 01:00:008-KStáhnout
2022-06-27 00:00:008-KStáhnout
2022-06-13 01:00:008-KStáhnout
2022-06-13 00:00:008-KStáhnout
2022-05-31 01:00:008-KStáhnout
2022-05-31 00:00:008-KStáhnout
2022-05-24 01:00:008-KStáhnout
2022-05-24 00:00:008-KStáhnout
2022-05-16 01:00:008-KStáhnout
2022-05-16 00:00:008-KStáhnout
2022-05-05 01:00:008-KStáhnout
2022-05-05 01:00:0010-QStáhnout
2022-05-05 00:00:008-KStáhnout
2022-05-05 00:00:0010-QStáhnout
2022-04-27 01:00:008-KStáhnout
2022-04-27 00:00:008-KStáhnout
2022-04-11 01:00:008-KStáhnout
2022-04-11 00:00:008-KStáhnout
2022-04-08 01:00:008-KStáhnout
2022-04-08 00:00:008-KStáhnout
2022-02-24 00:00:008-KStáhnout
2022-02-24 00:00:0010-KStáhnout
2022-02-23 23:00:008-KStáhnout
2022-02-23 23:00:0010-KStáhnout
2021-11-17 00:00:008-KStáhnout
2021-11-16 23:00:008-KStáhnout
2021-11-10 00:00:008-KStáhnout
2021-11-10 00:00:0010-QStáhnout
2021-11-09 23:00:008-KStáhnout
2021-11-09 23:00:0010-QStáhnout
2021-08-12 01:00:008-KStáhnout
2021-08-12 01:00:0010-QStáhnout
2021-08-12 00:00:008-KStáhnout
2021-08-12 00:00:0010-QStáhnout
2021-07-01 01:00:008-KStáhnout
2021-07-01 00:00:008-KStáhnout
2021-06-28 01:00:008-KStáhnout
2021-06-28 00:00:008-KStáhnout
2021-06-08 01:00:008-KStáhnout
2021-06-08 00:00:008-KStáhnout
2021-05-17 01:00:008-KStáhnout
2021-05-17 01:00:0010-QStáhnout
2021-05-17 00:00:008-KStáhnout
2021-05-17 00:00:0010-QStáhnout
2021-04-06 01:00:008-KStáhnout
2021-04-06 00:00:008-KStáhnout
2021-03-25 00:00:008-KStáhnout
2021-03-25 00:00:0010-KStáhnout
2021-03-24 23:00:008-KStáhnout
2021-03-24 23:00:0010-KStáhnout
2021-03-19 00:00:008-KStáhnout
2021-03-18 23:00:008-KStáhnout
2021-02-10 00:00:008-KStáhnout
2021-02-09 23:00:008-KStáhnout
2020-11-09 00:00:008-KStáhnout
2020-11-09 00:00:0010-QStáhnout
2020-11-08 23:00:008-KStáhnout
2020-11-08 23:00:0010-QStáhnout
2020-10-02 01:00:008-KStáhnout
2020-10-02 00:00:008-KStáhnout
2020-08-13 01:00:008-KStáhnout
2020-08-13 01:00:0010-QStáhnout
2020-08-13 00:00:008-KStáhnout
2020-08-13 00:00:0010-QStáhnout
2020-07-31 01:00:008-KStáhnout
2020-07-31 00:00:008-KStáhnout
2020-07-02 01:00:008-KStáhnout
2020-07-02 00:00:008-KStáhnout
2020-05-15 01:00:008-KStáhnout
2020-05-15 01:00:0010-QStáhnout
2020-05-15 00:00:008-KStáhnout
2020-05-15 00:00:0010-QStáhnout
preloader